Open AccessHydroxychloroquine in a G6PD-Deficient Patient with COVID-19 Complicated by Haemolytic Anaemia: Culprit or Innocent Bystander
Author(s) -
François Mastroianni,
Vincent Colombié,
Géraldine Claes,
Axelle Gilles,
Frédéric Vandergheynst,
Sammy Place
Publication year - 2020
Publication title -
european journal of case reports in internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 1
ISSN - 2284-2594
DOI - 10.12890/2020_001875
Subject(s) - hydroxychloroquine , medicine , context (archaeology) , culprit , covid-19 , pediatrics , bystander effect , chloroquine , malaria , immunology , disease , myocardial infarction , infectious disease (medical specialty) , paleontology , biology
Hydroxychloroquine has been used worldwide as a first-line treatment for patients hospitalized with COVID-19. Little is known about COVID-19 and its effects on patients with congenital red blood cell disorders. We report a case of haemolytic anaemia in a 32-year-old patient and a fortuitous highlighting of G6PD deficiency. We reviewed the literature to assess the risk of hydroxychloroquine use in this context.